These compounds represent valuable starting points for developing next-generation therapeutics targeting DGK-α-mediated signaling pathways in cancer, inflammatory disorders, and viral infections, with potential advantages over existing inhibitors, including improved selectivity and reduced off-target effects. The gene discussed is DGKA; the disease is viral infectious disease.